Skip to main
CRMD

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix is a promising biopharmaceutical company with a strong focus on developing and commercializing therapeutic products for life-threatening diseases and conditions. The company's lead product, DefenCath, has shown positive results in preventing infections in hemodialysis patients and has potential for expansion into other treatment settings. With strong partnerships in place and a growing market opportunity, there is potential for significant revenue growth in the coming years. As such, this financial analyst has a positive outlook on Cormedix's stock.

Bears say

Cormedix is a clinical-stage biopharmaceutical company with only one product, DefenCath, in its pipeline, which has faced challenges in clinical trial enrollment and negative results. While their recently released ReSPECT data showed competitive efficacy, there is still uncertainty about the potential commercial success and market share for DefenCath. Additionally, Cormedix's reliance on one product and their lack of diversity in their management team and pipeline are cause for concern.

CorMedix (CRMD) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Buy based on their latest research and market trends.

According to 7 analysts, CorMedix (CRMD) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.